Nivolumab + Tacrolimus + Prednisone ± Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous Cancers.
Kara M SchenkJulie Stein DeutschSunandana ChandraDiwakar DavarZeynep ErogluNikhil I KhushalaniJason John LukePatrick A OttJeffrey A SosmanVikram AggarwalMegan D SchollenbergerWilliam H SharfmanKristin P BibeeJeffrey F ScottManisha J LossHao WangHanfei QiElad SharonHoward StreicherHelen X ChenRobert N WoodwardSerena M BagnascoJanis M TaubeSuzanne L TopalianDaniel C BrennanEvan J LipsonPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
In most KTR with advanced skin cancer, TACRO + PRED provides insufficient allograft protection and compromises immune-mediated tumor regression after administration of NIVO ± IPI. Elevated dd-cfDNA levels can signal treatment-related allograft rejection earlier than rises in serum creatinine.